Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

NCT05608005 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

581

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza
Healthy Volunteers

Interventions

BIOLOGICAL: Panblok + MF59 Dose 1
BIOLOGICAL: Panblok + MF59 Dose 2
BIOLOGICAL: Unadjuvanted Panblok Dose 3

Sponsor

Sanofi Pasteur, a Sanofi Company